USA - engelsk - NLM (National Library of Medicine)

jubilant hollisterstier llc - apis mellifera venom (unii: 76013o881m) (apis mellifera venom - unii:76013o881m) - apis mellifera venom 100 ug in 1 ml - insect stings may induce a wide range of allergic symptoms in sensitive patients. a normal sting response is initial burning or stinging pain that may be intense and last several minutes to an hour or more. there is usually some local swelling coming on immediately and persisting for several days. the location of the sting has considerable influence on the intensity of the pain and extent of swelling. stings on the fingers or feet produce much pain, but less swelling; whereas a sting on the head or face produces extensive swelling with variable pain. local reactions coming on rapidly and larger than the usual local reaction, particularly if the swelling spans both adjacent joints on the extremities, can indicate hypersensitivity. systemic symptoms come on shortly after the sting, often within seconds to minutes. symptoms may range from generalized flushing, itching, redness, diffuse swelling of the skin or urticarial wheals, abdominal cramps, nausea, vomiting, or incontinence of urine or stool, to faintness

Tanzania - engelsk - Tanzania Medicinces & Medical Devices Authority

alfa pharmaceuticals limited, tanzania - sodium chloride & glucose intravenous infusion bp (0.9% w/v & 5% w/v) - intravenous infusion - 0.9% & 5%

Kenya - engelsk - Pharmacy and Poisons Board

aculife healthcare pvt ltd commerce house-v, besides vodafone house, prahlad - compound sodium lactate intravenous infusion b.p… - infusion - each 100 ml contains sodium lactate 0.320 gm… - intravenous solutions: solutions affecting the

Kenya - engelsk - Pharmacy and Poisons Board

questa care inc. c/o. surgilinks ltd 4251, s. higuera st. suite 800, san luis obispo - glucose intravenous infusion bp - infusion - 10% w/v (100 gm/l) - intravenous solutions: solutions for parenteral

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - magnesium chloride hexahydrate, quantity: 17 g/l; calcium chloride dihydrate, quantity: 24 g/l - injection, intravenous infusion - excipient ingredients: water for injections - calcium and magnesium chloride intravenous infusion is used in conjunction with citrate haemofiltration replacemnet solution, for the replacement of calcium and magnesium

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; benzyl alcohol; water for injections - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation. cordarone x intravenous may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. cordarone x intravenous should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alexion pharmaceuticals australasia pty ltd - sebelipase alfa, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections; albumin - kanuma (sebelipase alfa rce) is indicated for long-term enzyme replacement therapy (ert) in patients of all ages with lysosomal acid lipase deficiency (lal-d).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 40 g - injection, intravenous infusion - excipient ingredients: proline - privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of the following conditions. 1.1 primary humoral immunodeficiency privigen indicated as replacement therapy for primary humoral immunodeficiency (pi). this includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (cvid), x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. 1.2 chronic immune thrombocytopenic purpura privigen is indicated for the treatment of patients with chronic immune thrombocytopenic purpura (itp) to raise platelet counts. 1.3 chronic inflammatory demyelinating polyneuropathy privigen is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. limitation of use: privigen maintenance therapy in cidp has not been studied for periods longer than 6 months. after responding during an initial treatment period, not all patients require indefinite maintenance therapy with privigen in order to remain free of cidp symptoms. individualize the duration of any treatment beyond 6 months based upon the patient?s response and demonstrated need for continued therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 10 g - injection, intravenous infusion - excipient ingredients: proline - privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of the following conditions. 1.1 primary humoral immunodeficiency privigen indicated as replacement therapy for primary humoral immunodeficiency (pi). this includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (cvid), x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. 1.2 chronic immune thrombocytopenic purpura privigen is indicated for the treatment of patients with chronic immune thrombocytopenic purpura (itp) to raise platelet counts. 1.3 chronic inflammatory demyelinating polyneuropathy privigen is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. limitation of use: privigen maintenance therapy in cidp has not been studied for periods longer than 6 months. after responding during an initial treatment period, not all patients require indefinite maintenance therapy with privigen in order to remain free of cidp symptoms. individualize the duration of any treatment beyond 6 months based upon the patient?s response and demonstrated need for continued therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 5 g - injection, intravenous infusion - excipient ingredients: proline - privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of the following conditions. 1.1 primary humoral immunodeficiency privigen indicated as replacement therapy for primary humoral immunodeficiency (pi). this includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (cvid), x-linked agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. 1.2 chronic immune thrombocytopenic purpura privigen is indicated for the treatment of patients with chronic immune thrombocytopenic purpura (itp) to raise platelet counts. 1.3 chronic inflammatory demyelinating polyneuropathy privigen is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (cidp) to improve neuromuscular disability and impairment. limitation of use: privigen maintenance therapy in cidp has not been studied for periods longer than 6 months. after responding during an initial treatment period, not all patients require indefinite maintenance therapy with privigen in order to remain free of cidp symptoms. individualize the duration of any treatment beyond 6 months based upon the patient?s response and demonstrated need for continued therapy.